The Past, the Present and the Future of Teledermatology: A Narrative Review

References

• Bashshur R, Shannon G, Krupinski E, Grigsby J. The taxonomy of telemedicine. Telemed J e-Health off J Am Telemed Assoc. 2011;17(6):484–494. doi:10.1089/tmj.2011.0103
   PubMed Web of Science ®Google Scholar
• McKoy K, Halpern S, Mutyambizi K. International Teledermatology Review. Curr Dermatol Rep. 2021;10(3):55–66. doi:10.1007/s13671-021-00333-6
   PubMed Web of Science ®Google Scholar
• Maddukuri S, Patel J, Lipoff JB. Teledermatology addressing disparities in health care access: a review. Curr Dermatol Rep. 2021;10(2):40–47. doi:10.1007/s13671-021-00329-2
   PubMed Web of Science ®Google Scholar
• Villani A, Scalvenzi M, Fabbrocini G. Teledermatology: a useful tool to fight COVID-19. J DermatolTreat. 2020;31(4):325. doi:10.1080/09546634.2020.1750557
   Google Scholar
• Coates SJ, Kvedar J, Granstein RD. Teledermatology: from historical perspective to emerging techniques of the modern era: part I: history, rationale, and current practice. J Am Acad Dermatol. 2015;72(4):563–566. doi:10.1016/j.jaad.2014.07.061
   PubMed Web of Science ®Google Scholar
• Perednia DA, Brown NA. Teledermatology: one application of telemedicine. Bull Med Libr Assoc. 1995;83(1):42–47.
   PubMedGoogle Scholar
• Wurm EMT, Hofmann-Wellenhof R, Wurm R, Soyer HP. Telemedicine and teledermatology: past, present and future. J der Dtsch Dermatologischen Gesellschaft. 2008;6(2):106–112. doi:10.1111/j.1610-0387.2007.06440.x
   PubMed Web of Science ®Google Scholar
• Crichton C, Macdonald S, Potts S, et al. Teledermatology in Scotland. J Telemed Telecare. 1995;1(3):185. doi:10.1177/1357633X9500100310
   PubMedGoogle Scholar
• Tensen E, van der Heijden JP, Jaspers MWM, Witkamp L. Two decades of teledermatology: current status and integration in National Healthcare Systems. Curr Dermatol Rep. 2016;5:96–104. doi:10.1007/s13671-016-0136-7
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Wu J, Kovarik CL, et al. State of teledermatology programs in the United States. J Am Acad Dermatol. 2012;67(5):939–944. doi:10.1016/j.jaad.2012.02.019
   PubMed Web of Science ®Google Scholar
• Yim KM, Florek AG, Oh DH, McKoy K, Armstrong AW. Teledermatology in the United States: an update in a dynamic era. Telemed J e-Health off J Am Telemed Assoc. 2018;24(9):691–697. doi:10.1089/tmj.2017.0253
   PubMed Web of Science ®Google Scholar
• López-Liria R, Valverde-Martínez MÁ, López-Villegas A, et al. Teledermatology versus face-to-face dermatology: an analysis of cost-effectiveness from eight studies from Europe and the United States. Int J Environ Res Public Health. 2022;19(5). doi:10.3390/ijerph19052534
   PubMed Web of Science ®Google Scholar
• Hwang JS, Lappan CM, Sperling LC, Meyerle JH. Utilization of telemedicine in the U.S. military in a deployed setting. Mil Med. 2014;179(11):1347–1353. doi:10.7205/MILMED-D-14-00115
   PubMed Web of Science ®Google Scholar
• van der Heijden JP, Spuls PI, Voorbraak FP, de Keizer NF, Witkamp L, Bos JD. Tertiary teledermatology: a systematic review. Telemed J e-Health off J Am Telemed Assoc. 2010;16(1):56–62. doi:10.1089/tmj.2009.0020
   PubMed Web of Science ®Google Scholar
• Abbott LM, Miller R, Janda M, et al. Practice guidelines for teledermatology in Australia. Australas J Dermatol. 2020;61(3):e293–e302. doi:10.1111/ajd.13301
   PubMed Web of Science ®Google Scholar
• Tognetti L, Fiorani D, Russo F, et al. Teledermatology in 2020: past, present and future perspectives. Ital J Dermatol Venereol. 2021;156(2):198–212. doi:10.23736/S2784-8671.21.06731-6
   PubMedGoogle Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022;11(6). doi:10.3390/jcm11061511
   Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Zakaria A, Miclau TA, Maurer T, Leslie KS, Amerson E. Cost minimization analysis of a teledermatology triage system in a managed care setting. JAMA dermatol. 2021;157(1):52–58. doi:10.1001/jamadermatol.2020.4066
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036. doi:10.1136/bmj.m1036
   PubMed Web of Science ®Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to “Cutaneous adverse effects of the available COVID-19 vaccines in India: a questionnaire-based study”. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18341
   Web of Science ®Google Scholar
• Habas K, Nganwuchu C, Shahzad F, et al. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther. 2020;18(12):1201–1211. doi:10.1080/14787210.2020.1797487
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. Clin Cosmet Invest Dermatol. 2022;15:2785–2793. doi:10.2147/CCID.S377029
   PubMed Web of Science ®Google Scholar
• Ibrahim AE, Magdy M, Khalaf EM, Mostafa A, Arafa A. Teledermatology in the time of COVID-19. Int J Clin Pract. 2021;75(12):e15000. doi:10.1111/ijcp.15000
   PubMed Web of Science ®Google Scholar
• Potestio L, Napolitano M, Bennardo L, Fabbrocini G, Patruno C. Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.17964
   Google Scholar
• Potestio L, Fabbrocini G, D’Agostino M, Piscitelli I, Martora F. Cutaneous reactions following COVID-19 vaccination: the evidence says “less fear”. J Cosmet Dermatol. 2023;22(1):28–29. doi:10.1111/jocd.15533
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32–33. doi:10.1111/jocd.15414
   PubMed Web of Science ®Google Scholar
• Potestio L, Villani A, Fabbrocini G, Martora F. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? J Cosmet Dermatol. 2022. doi:10.1111/jocd.15331
   Web of Science ®Google Scholar
• Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines Reply to “cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience”. J Eur Acad Dermatol Venereol. 2023;37(1):e43–e44. doi:10.1111/jdv.18531
   PubMed Web of Science ®Google Scholar
• Villani A, Megna M, Scalvenzi M, Fabbrocini G, Ruggiero A. Teledermatology and chronic skin diseases: real life experience in a Southern Italian Dermatologic Centre. Dermatol Ther. 2020;33(6):e13839. doi:10.1111/dth.13839
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Sweren RJ, Grossberg AL. Dermatology practices as vectors for COVID-19 transmission: a call for immediate cessation of nonemergent dermatology visits. J Am Acad Dermatol. 2020;82(5):e179–e180. doi:10.1016/j.jaad.2020.03.037
   PubMed Web of Science ®Google Scholar
• Radi G, Diotallevi F, Campanati A, Offidani A. Global coronavirus pandemic (2019-nCOV): implication for an Italian medium size dermatological clinic of a II level hospital. J Eur Acad Dermatol Venereol. 2020;34(5):e213–e214. doi:10.1111/jdv.16386
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Annunziata MC, Fabbrocini G, Megna M. Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic. J Eur Acad Dermatol Venereol. 2020;34(6):e249. doi:10.1111/jdv.16476
   PubMed Web of Science ®Google Scholar
• Stadler PC, Senner S, Frey S, et al. Teledermatology in times of COVID-19. J Dermatol. 2021;48(5):620–624. doi:10.1111/1346-8138.15812
   PubMed Web of Science ®Google Scholar
• Sharma A, Jindal V, Singla P, Goldust M, Mhatre M. Will teledermatology be the silver lining during and after COVID-19? Dermatol Ther. 2020;33(4):e13643. doi:10.1111/dth.13643
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Megna M, et al. Teledermatology for common inflammatory skin conditions: the medicine of the future? Life. 2023;13(4). doi:10.3390/life13041037
   PubMedGoogle Scholar
• Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J DermatolTreat. 2022:1–6. doi:10.1080/09546634.2022.2102121
   Google Scholar
• Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242–249. doi:10.1097/ACI.0000000000000837
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498. doi:10.1111/jdv.18137
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021:e15120. doi:10.1111/dth.15120
   PubMed Web of Science ®Google Scholar
• Lacarrubba F, Dini V, Napolitano M, et al. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience. J Eur Acad Dermatol Venereol. 2019;33(Suppl 6):10–14. doi:10.1111/jdv.15847
   PubMedGoogle Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022. doi:10.1111/ced.15395
   Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Piaserico S, Di Leo S, Cazzaniga S, Naldi L. Preference for telemedicine versus in-person visit among patients with psoriasis receiving biological drugs. Dermatol Ther. 2021;11(4):1333–1343. doi:10.1007/s13555-021-00555-3
   Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Cohn E, Han G. Teledermatology: a Postpandemic Update. Cutis. 2023;112(5):209–211. doi:10.12788/cutis.0882
   PubMed Web of Science ®Google Scholar
• Liopyris K, Gregoriou S, Dias J, Stratigos AJ. Artificial intelligence in dermatology: challenges and perspectives. Dermatol Ther. 2022;12(12):2637–2651. doi:10.1007/s13555-022-00833-8
   Web of Science ®Google Scholar
• Li Z, Koban KC, Schenck TL, Giunta RE, Li Q, Sun Y. Artificial intelligence in dermatology image analysis: current developments and future trends. J Clin Med. 2022;11(22). doi:10.3390/jcm11226826
   Web of Science ®Google Scholar
• Scheetz J, Rothschild P, McGuinness M, et al. A survey of clinicians on the use of artificial intelligence in ophthalmology, dermatology, radiology and radiation oncology. Sci Rep. 2021;11(1):5193. doi:10.1038/s41598-021-84698-5
   PubMed Web of Science ®Google Scholar
• Monheit G, Cognetta AB, Ferris L, et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol. 2011;147(2):188–194. doi:10.1001/archdermatol.2010.302
   PubMed Web of Science ®Google Scholar
• Navarrete-Dechent C, Dusza SW, Liopyris K, Marghoob AA, Halpern AC, Marchetti MA. Automated dermatological diagnosis: hype or reality? J Invest Dermatol. 2018;138(10):2277–2279. doi:10.1016/j.jid.2018.04.040
   PubMed Web of Science ®Google Scholar
• Khullar D, Casalino LP, Qian Y, Lu Y, Krumholz HM, Aneja S. Perspectives of patients about artificial intelligence in health care. JAMA Network Open. 2022;5(5):e2210309. doi:10.1001/jamanetworkopen.2022.10309
   PubMed Web of Science ®Google Scholar
• Ly S, Reyes-Hadsall S, Drake L, et al. Public perceptions, factors, and incentives influencing patient willingness to share clinical images for artificial intelligence-based healthcare tools. Dermatol Ther. 2023;13(11):2895–2902. doi:10.1007/s13555-023-01031-w
   Google Scholar
• Potestio L, Martora F, Villani A, Ruggiero A, Scalvenzi M, Megna M. ChatGPT and Dermatology: friends or foes? Clin Exp Dermatol. 2023. doi:10.1093/ced/llad227
   Web of Science ®Google Scholar
• Pathipati AS, Lee L, Armstrong AW. Health-care delivery methods in teledermatology: consultative, triage and direct-care models. J Telemed Telecare. 2011;17(4):214–216. doi:10.1258/jtt.2010.010002
   PubMed Web of Science ®Google Scholar
• Landow SM, Mateus A, Korgavkar K, Nightingale D, Weinstock MA. Teledermatology: key factors associated with reducing face-to-face dermatology visits. J Am Acad Dermatol. 2014;71(3):570–576. doi:10.1016/j.jaad.2014.02.021
   PubMed Web of Science ®Google Scholar
• Ahuja S, Briggs SM, Collier SM. Teledermatology in rural, underserved, and isolated environments: a review. Curr Dermatol Rep. 2022;11(4):328–335. doi:10.1007/s13671-022-00377-2
   PubMed Web of Science ®Google Scholar
• Suneja T, Smith ED, Chen GJ, Zipperstein KJ, Fleischer ABJ, Feldman SR. Waiting times to see a dermatologist are perceived as too long by dermatologists: implications for the dermatology workforce. Arch Dermatol. 2001;137(10):1303–1307. doi:10.1001/archderm.137.10.1303
   PubMedGoogle Scholar
• Villani A, Scalvenzi M, Micali G, et al. Management of advanced invasive melanoma: new strategies. Adv Ther. 2023;40(8):3381–3394. doi:10.1007/s12325-023-02555-5
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, Scalvenzi M. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164–1178. doi:10.1007/s12325-022-02044-1
   PubMed Web of Science ®Google Scholar
• Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2022;21(1):21–29. doi:10.1080/14740338.2022.1993819
   PubMed Web of Science ®Google Scholar
• Picone V, Martora F, Fabbrocini G, Marano L. “Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225
   PubMed Web of Science ®Google Scholar
• Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
   PubMed Web of Science ®Google Scholar
• Picone V, Fabbrocini G, Martora L, Martora F. A case of new-onset lichen planus after COVID-19 vaccination. Dermatol Ther. 2022;12(3):801–805. doi:10.1007/s13555-022-00689-y
   Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, Megna M. Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
   PubMed Web of Science ®Google Scholar
• Pasquali P, Sonthalia S, Moreno-Ramirez D, et al. Teledermatology and its current perspective. Indian Dermatol Online J. 2020;11(1):12–20. doi:10.4103/idoj.IDOJ_241_19
   PubMedGoogle Scholar
• Arimany-Manso J, Pujol RM, García-Patos V, Saigí U, Martin-Fumadó C. Medicolegal aspects of teledermatology. Actas Dermosifiliogr. 2020;111(10):815–821. doi:10.1016/j.ad.2020.08.008
   PubMed Web of Science ®Google Scholar
• Giansanti D. The Artificial Intelligence in Teledermatology: a narrative review on opportunities, perspectives, and bottlenecks. Int J Environ Res Public Health. 2023;20(10). doi:10.3390/ijerph20105810
   PubMedGoogle Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;1–16. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar